 |
| GlaxoSmithKline / gsk.com |
PT GlaxoSmithKline Indonesia - GSK Indonesia is a foreign investment company in Indonesia who invests in healthcare and pharmaceutical business. The Company is a local subsidiary of GlaxoSmithKline (GSK), a global healthcare and pharmaceutical giant based in Brentford London UK. In Indonesia, GSK is based in Jakarta and supported by 2 business units, namely GSK Pharmaceuticals and GSK Consumer Healthcare. GSK Pharmaceuticals engaged in ethical and vaccine products, while GSK Consumer Healthcare has focuses to sells Consumer Healthcare products with principal brands such as Panadol, Sensodyne and Scotts. GSK Indonesia achieved significant performance over the last five years. GSK Indonesia booked £50 million (equivalent with Rp 950 billion) in net sales in 2013, up from around £16 million in 2008. This was stated by GSK on its news release issued on 28 March 2014 as cited by BursaKerja.top.com.
To support GSK Sales business growth and achievements, in GSK Pharmaceuticals for ethical and vaccine products or GSK Consumer Healthcare, PT GlaxoSmithKline Indonesia is looking for qualified personnel with high motivation, initiative and integrity to fill in the following positions:
Future Leader Program - Sales Management Trainee (Code : FLP 2014)
Requirements
- Bachelor degree (S1) in any major with minimum GPA of 3.00.
- Has strong interest and passion in Sales and Healthcare Industry.
- Willing to be stationed across Indonesia during sales assignmen .
- Possess driving license (SIM A & SIM C).
- Excellent verbal and written communication skills in English
- Good computer literacy.
For further information, please refer official source from GSK Indonesia through ITB Career Center on following link below. Those who have close qualifications above are encouraged to send your updated CV no later than 12 June 2014 to hr.recruitment-indonesia@gsk.com and state position code (FLP 2014) as the email subject. Only qualified candidate match with the above mentioned qualifications will be notified for further selection. (BursaKerja.top.com/Source)
0 comments:
Post a Comment